AU2020373165A1 - Anti-mullerian hormone polypeptides - Google Patents

Anti-mullerian hormone polypeptides Download PDF

Info

Publication number
AU2020373165A1
AU2020373165A1 AU2020373165A AU2020373165A AU2020373165A1 AU 2020373165 A1 AU2020373165 A1 AU 2020373165A1 AU 2020373165 A AU2020373165 A AU 2020373165A AU 2020373165 A AU2020373165 A AU 2020373165A AU 2020373165 A1 AU2020373165 A1 AU 2020373165A1
Authority
AU
Australia
Prior art keywords
amh
seq
analogue
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020373165A
Other languages
English (en)
Inventor
Craig Anthony Harrison
Kelly Louise Walton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904097A external-priority patent/AU2019904097A0/en
Application filed by Monash University filed Critical Monash University
Publication of AU2020373165A1 publication Critical patent/AU2020373165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
AU2020373165A 2019-10-30 2020-10-30 Anti-mullerian hormone polypeptides Abandoned AU2020373165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904097A AU2019904097A0 (en) 2019-10-30 Anti-mullerian hormone polypeptides
AU2019904097 2019-10-30
PCT/AU2020/051187 WO2021081601A1 (en) 2019-10-30 2020-10-30 Anti-mullerian hormone polypeptides

Publications (1)

Publication Number Publication Date
AU2020373165A1 true AU2020373165A1 (en) 2022-05-26

Family

ID=75714709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020373165A Abandoned AU2020373165A1 (en) 2019-10-30 2020-10-30 Anti-mullerian hormone polypeptides

Country Status (8)

Country Link
US (1) US20220411477A1 (cg-RX-API-DMAC10.html)
EP (1) EP4051699A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023501308A (cg-RX-API-DMAC10.html)
KR (1) KR20220155980A (cg-RX-API-DMAC10.html)
CN (1) CN114945588A (cg-RX-API-DMAC10.html)
AU (1) AU2020373165A1 (cg-RX-API-DMAC10.html)
CA (1) CA3156607A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021081601A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049960A1 (en) * 2023-08-30 2025-03-06 University Of Cincinnati Enhancing the production of anti-mullerian hormone through modification of its prodomain
WO2025085972A1 (en) * 2023-10-27 2025-05-01 Monash University Anti-mullerian hormone agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693144A1 (en) * 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
WO2010017290A1 (en) * 2008-08-05 2010-02-11 The Trustees Of Columbia University In The City Of New York Müllerian inhibiting substance (mis) analogues
CA2837472A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
HK1215259A1 (zh) * 2012-11-09 2016-08-19 Ansh Labs Llc 檢測抗苗勒管激素的同種型的抗體組合物及免疫測定方法
US11230583B2 (en) * 2015-11-26 2022-01-25 Hudson Institute of Medical Research Inhibin analogs
EP3257867A1 (fr) * 2016-06-17 2017-12-20 Biomérieux Procédé de préparation d'anticorps anti-amh et leurs utilisations
US11518793B2 (en) * 2016-12-14 2022-12-06 The General Hospital Corporation Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
WO2018148649A1 (en) * 2017-02-10 2018-08-16 The Institute For Cancer Research D/B/A Chimera of bone morphogenic protein 2 and the müllerian-inhibiting substance type ii receptor binding region of mullerian-inhibiting substance

Also Published As

Publication number Publication date
JP2023501308A (ja) 2023-01-18
EP4051699A1 (en) 2022-09-07
KR20220155980A (ko) 2022-11-24
US20220411477A1 (en) 2022-12-29
CN114945588A (zh) 2022-08-26
EP4051699A4 (en) 2024-01-17
WO2021081601A1 (en) 2021-05-06
CA3156607A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
CN103930134B (zh) 长效促黄体激素(lh)化合物
JP2024075579A (ja) 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
US10869909B2 (en) Compositions and methods of use for treating metabolic disorders
AU2022271391A1 (en) Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
JP6698015B2 (ja) 疾患の治療のための改変されたミュラー管抑制物質(mis)タンパク質およびその使用
AU2024203142B2 (en) C3b binding polypeptide
JP7488303B2 (ja) IgE Fc受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法
US20200376082A1 (en) Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
US20220411477A1 (en) Anti-mullerian hormone polypeptides
EP3096775B1 (en) Socs mimetics for the treatment of diseases
KR20190084886A (ko) IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물
US8546324B2 (en) Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
WO2025085972A1 (en) Anti-mullerian hormone agonists
Wang et al. Insulin receptor binding motif tagged with IgG4 Fc (Yiminsu) works as an insulin sensitizer to activate Akt signaling in hepatocytes
HK40076899A (en) Use of mullerian inhibiting substance (mis) proteins for contraception

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period